Abstract:Background Antibody-drug conjugates (ADCs) targeting the RON receptor, a tumorigenic factor contributing to cancer malignancy, has been considered as a novel strategy for cancer therapy. Here we describe a humanized antibody recognizing the RON plexin-semaphorin-integrin (PSI) domain with increased drug delivery capability for potential clinical application. Method Monoclonal antibody PCM5B14 specific to the human and monkey RON PSI domain was generated and characterized by various immunological methods. Humanized antibody H5B14 was created by grafting PCM5B14 complementarity-determining regions into human IgG1/κ acceptor frameworks and conjugated with monomethyl auristatin E and duocarmycin to form two H5B14-based ADCs. Stability of H5B14-based ADCs in human plasma was measured using hydrophobic interaction chromatography. Various biochemical and biological assays were used to determine ADC- regulated RON internalization, cell viability, spheroid formation, and death of cancer stem-like cells. Efficacies of H5B14-based ADCs in vivo were validated using tumor xenograft models. Maximal tolerated doses of H5B14-based ADCs were established in mice. Results H5B14 was highly specific to the human RON PSI domain and superior over other anti-RON ADCs in induction of RON internalization in various cancer cell lines tested. H5B14-based ADCS had a drug to antibody ratio of ~ 3.70:1 and were stable in human plasma with a minimal dissociation within a 10-day period. Functionally, H5B14-mediated drug delivery decreased cell viability at early stages with an average IC 50 at ~ 20 nM in multiple cancer cell lines examined. H5B14-based ADCs also inhibited spheroid formation and caused death of cancer stem-like cells with RON + /CD44 + /ESA + phenotypes. In vivo , H5B14-based ADCs in a single injection inhibited tumor xenograft growth mediated by multiple cancer cell lines. Tumoristatic concentrations calculated from xenograft tumor models were in the range of 0.63 to 2.0 mg/kg bodyweight. Significantly, H5B14-based ADCs were capable of eradicating tumors at variable levels across multiple xenograft models regardless their malignant statuses. Toxicologically, H5B14-based ADCs were well tolerated in mice up to 60 mg/kg. Conclusion H5B14-based ADCs targeting the RON PSI domain are superior in inducing RON internalization, leading to robust drug delivery and overall inhibition and eradication of tumors in multiple xenograft models. These findings warrant H5B14-based ADCs for clinical trials in the future.

Anti‐Pan‐Rspo Chimeric Protein‐Conjugated Albumin Nanoparticle Provides Promising Opportunities in Cancer Targeted Therapy

Development of A Novel RON Targeted Antibody‐Drug Conjugates Using Cysteine Bridging Technology for Potential Treatment of Pancreatic Cancer

Development Of A Novel Ron Receptor Targeted Antibody-Drug Conjugates Using Cysteine Bridging Technology For Potential Treatment Of Pancreatic Cancer

Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase.

Targeting RON Receptor Tyrosine Kinase for Treatment of Advanced Solid Cancers: Antibody–drug Conjugates As Lead Drug Candidates for Clinical Trials

Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody-drug conjugates as lead drug candidates for clinical trials.

Therapeutic Efficacy of a Novel Humanized Antibody-Drug Conjugate Recognizing Plexin-Semaphorin-integrin Domain in the RON Receptor for Targeted Cancer Therapy.

Rgd-Conjugated Albumin Nanoparticles As A Novel Delivery Vehicle in Pancreatic Cancer Therapy

Drug Conjugates of Antagonistic RSPO4 Mutant For Simultaneous Targeting of LGR4/5/6 for Cancer Treatment

Self-Reinforced Cancer Targeting (SRCT) Depending on Reciprocally Enhancing Feedback between Targeting and Therapy

Sustained Expression Of The Ron Receptor Tyrosine Kinase By Pancreatic Cancer Stem Cells As A Potential Targeting Moiety For Antibody-Directed Chemotherapeutics

Two‐Step Targeting‐Tunable Semiconducting Nanoswitches Amplify Mitochondrion Damage and PD‐L1 Blockade for Orthotopic Pancreatic Cancer Therapy

Chimeric Peptide Engineered Nanomedicine for Synergistic Suppression of Tumor Growth and Therapy-Induced Hyperlipidemia by mTOR and PCSK9 Inhibition

A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapy

Sequential responsive nano-PROTACs for precise intracellular delivery and enhanced degradation efficacy in colorectal cancer therapy

Mitigation of Anti‐Drug Antibody Production for Augmenting Anticancer Efficacy of Therapeutic Protein via Co‐Injection of Nano‐Rapamycin

Smart R848-Loaded Nanoparticles Based on Copper Chelate Copolymer for Combining Anti-Angiogenesis and Immunotherapy to Inhibit Breast Cancer Growth and Metastasis

Modulating the tumoral SPARC content to enhance albumin-based drug delivery for cancer therapy

Redox-Responsive Molecularly Imprinted Nanoparticles for Targeted Intracellular Delivery of Protein Toward Cancer Therapy.

Dual‐Programmable Semiconducting Polymer NanoPROTACs for Deep‐Tissue Sonodynamic‐Ferroptosis Activatable Immunotherapy

Hierarchical Nanoassemblies-Assisted Combinational Delivery of Cytotoxic Protein and Antibiotic for Effective Cancer Treatment.